Literature DB >> 16986068

Long-term GERD management: the individualized approach.

Guido Tytgat1.   

Abstract

Gastroesophageal reflux disease (GERD) is a complex condition, and both mucosal lesions and symptoms are important parameters in evaluating disease severity and the impact of treatment. An individualized approach in which treatment is tailored to each patient is the appropriate strategy. Treatment with a standard dose of a proton pump inhibitor (PPI) should be continued until symptoms resolve in the case of nonerosive reflux disease (NERD), or until complete remission is achieved (resolution of symptoms and endoscopically confirmed healing) in patients with erosive disease. Maintenance treatment with a half-dose PPI is effective in both erosive esophagitis and NERD. If NERD patients remain in remission with the half-dose PPI, therapy can continue in an on-demand basis. A relapse of symptoms often needs to be treated by a return to a full-dose PPI. Studies of long-term treatment with PPIs show that they are a safe and effective means of maintaining remission in patients with GERD. copyright (c) 2006 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16986068

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  3 in total

1.  Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors.

Authors:  Luigi Monaco; Antonio Brillantino; Francesco Torelli; Michele Schettino; Giuseppe Izzo; Angelo Cosenza; Natale Di Martino
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

2.  CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.

Authors:  Takahisa Furuta; Mitsushige Sugimoto; Chise Kodaira; Masafumi Nishino; Mihoko Yamade; Mutsuhiro Ikuma; Naohito Shirai; Hiroshi Watanabe; Kazuo Umemura; Michio Kimura; Akira Hishida
Journal:  Eur J Clin Pharmacol       Date:  2009-03-04       Impact factor: 2.953

3.  Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.

Authors:  Hung-Hsien Chiang; Deng-Chyang Wu; Pin-I Hsu; Chao-Hung Kuo; Wei-Chen Tai; Shih-Cheng Yang; Keng-Liang Wu; Chih-Chien Yao; Cheng-En Tsai; Chih-Ming Liang; Yao-Kuang Wang; Jiunn-Wei Wang; Chih-Fang Huang; Seng-Kee Chuah
Journal:  Drug Des Devel Ther       Date:  2019-04-26       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.